MannKind Corporation (MNKD)
NASDAQ:MNKD
Want to see MNKD full AI Analyst Report?
MNKD Stock Chart & Stats
$2.84
-$0.05(-0.80%)
At close: 4:00 PM EST
$2.84
-$0.05(-0.80%)
Day’s Range― - ―
52-Week Range$2.23 - $6.51
Previous CloseN/A
Volume434.88K
Average Volume (3M)5.60M
Market Cap
$1.00B
Enterprise Value$1.39B
Total Cash (Recent Filing)$133.86M
Total Debt (Recent Filing)$436.67M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 12, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding308,950,160
10 Day Avg. Volume9,669,023
30 Day Avg. Volume5,600,849
Financial Highlights & Ratios
PEG Ratio-3.69
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue3.85
Enterprise Value/Gross Profit5.06
Enterprise Value/Ebitda48.70
Forecast
1Y Price Target
$7.54Price Target Upside165.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.02
Revenue Forecast (FY)$459.90M
Bulls Say, Bears Say
Bulls Say
Labeling And DosingAn updated dosing conversion on the Afrezza label is expected to improve dosing accuracy, reduce under‑dosing, and encourage patients to switch from injections or insulin pumps to inhaled insulin, supporting sales growth.
Regulatory Approval (pediatrics)Initiation and first‑patient enrollment in a pediatric trial for Afrezza, together with an FDA label update, advance the path to pediatric approval and could expand the product's commercial population.
Revenue Diversification And PipelineAcquisition of scPharma and internal development of an inhaled nintedanib candidate broaden revenue sources beyond a single royalty and create potential new revenue streams if clinical programs and partnerships progress.
Bears Say
Partner Competition And RoyaltiesUnited Therapeutics' introduction of a soft mist inhaler and a new oral prostacyclin may reduce demand for the licensed dry powder formulation, creating downside pressure on royalty income.
Real‑world Efficacy And Adoption RiskReal‑world reports linking reduced Afrezza effectiveness to under‑dosing could limit clinician confidence and patient uptake unless dosing guidance and provider training successfully address correct use.
Royalty And Valuation UncertaintyUncertainty about how competing treatments and formulation changes will affect Tyvaso dry powder inhaler royalties increases valuation risk for the company.
MannKind News
MNKD FAQ
What was MannKind Corporation’s price range in the past 12 months?
MannKind Corporation lowest stock price was $2.23 and its highest was $6.51 in the past 12 months.
What is MannKind Corporation’s market cap?
MannKind Corporation’s market cap is $1.00B.
When is MannKind Corporation’s upcoming earnings report date?
MannKind Corporation’s upcoming earnings report date is Aug 12, 2026 which is in 83 days.
How were MannKind Corporation’s earnings last quarter?
MannKind Corporation released its earnings results on May 06, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.05.
Is MannKind Corporation overvalued?
According to Wall Street analysts MannKind Corporation’s price is currently Undervalued.
Does MannKind Corporation pay dividends?
MannKind Corporation does not currently pay dividends.
What is MannKind Corporation’s EPS estimate?
MannKind Corporation’s EPS estimate is -0.01.
How many shares outstanding does MannKind Corporation have?
MannKind Corporation has 308,950,160 shares outstanding.
What happened to MannKind Corporation’s price movement after its last earnings report?
MannKind Corporation reported an EPS of -$0.05 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went down -0.281%.
Which hedge fund is a major shareholder of MannKind Corporation?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.54 (165.34% Upside)
$7.54 (165.34% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 26.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $259.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.37%
12-Months-Change
Fundamentals
Return on Equity
45.59%
Trailing 12-Months
Asset Growth
81.50%
Trailing 12-Months
Company Description
MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple near-term commercial and clinical catalysts, solid top-line growth (15% YoY) and strong operational wins (FURO6 prescriber growth, royalties up 9%, SC Pharma synergies exceeding $20M), alongside meaningful progress on pipeline programs (MNKD-201 Phase 1b and Phase 2 start) and an expanded collaboration with United Therapeutics (ralinepag DPI payment and milestone potential). Short-term challenges include seasonality, field reorganization and inventory transitions that pressured Q1 revenue and contributed to GAAP and non-GAAP losses, plus some formulation and development uncertainty for new DPI programs. Management reiterated full-year FURO6 guidance and expects acceleration in H2 tied to the ReadyFlow auto-injector and Afrezza pediatrics launch, indicating confidence that near-term investments will drive longer-term growth.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$7.54
▲(165.34% Upside)
Technical Analysis
Ownership Overview
2.47% Insiders
10.66% Mutual Funds
9.64% Other Institutional Investors
60.63% Public Companies and
Individual Investors